Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 515 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Bone Marrow Collection Clear all
Completed No phase listed Observational

Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

NCT00898079
View directory record Official record
Conditions
Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Solid Neoplasm, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Neoplasm of Uncertain Malignant Potential, Prolymphocytic Leukemia, Secondary Acute Myeloid Leukemia, T-Cell Large Granular Lymphocyte Leukemia
Interventions
Cytology Specimen Collection Procedure
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
2,545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
175
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 132 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 25, 2026, 2:34 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

NCT04817241
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cytarabine, Daunorubicin, Decitabine and Cedazuridine, Venetoclax
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Birmingham, Alabama • New Haven, Connecticut • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 2:34 PM EDT
Completed Not applicable Interventional

Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases

NCT00376922
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Psychosocial Effects of Cancer and Its Treatment
Interventions
music therapy
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 25, 2026, 2:34 PM EDT
Recruiting Phase 1 Interventional

Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

NCT05755087
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Tegavivint, Bone Marrow Biopsy, Bone Marrow Aspiration
Procedure · Drug
Lead sponsor
Lapo Alinari
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 25, 2026, 2:34 PM EDT
Completed No phase listed Observational

Bereaved Parent Study

NCT02425787
View directory record Official record
Conditions
Bereavement
Interventions
Interview, Focus Group
Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 25, 2026, 2:34 PM EDT
Recruiting Phase 1 Interventional

Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation

NCT06735664
View directory record Official record
Conditions
Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography, Multigated Acquisition Scan, Odronextamab, Positron Emission Tomography, Ultrasound Imaging, Zanubrutinib
Procedure · Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 25, 2026, 2:34 PM EDT
Recruiting Phase 2 Interventional

Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT06757647
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
Acalabrutinib, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging of the Heart
Drug · Procedure
Lead sponsor
Seema Bhat
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 25, 2026, 2:34 PM EDT
Recruiting Phase 1 Interventional

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

NCT06222580
View directory record Official record
Conditions
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Gilteritinib, Revumenib, Echocardiography Test, Multigated Acquisition Scan
Procedure · Drug
Lead sponsor
Uma Borate
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Chapel Hill, North Carolina • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 25, 2026, 2:34 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

NCT03210714
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Osteosarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Refractory Childhood Malignant Germ Cell Tumor, Refractory Childhood Osteosarcoma, Refractory Childhood Rhabdomyosarcoma, Refractory Childhood Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Wilms Tumor
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Erdafitinib, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
114
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 2:34 PM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia

NCT00002831
View directory record Official record
Conditions
Leukemia
Interventions
Filgrastim, Busulfan, Cyclophosphamide, Cyclosporine, Decitabine (DAC), Methotrexate, Methylprednisolone, Tacrolimus, Allogeneic Bone Marrow Transplantation, Peripheral Blood Stem Cell Transplantation
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 25, 2026, 2:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma

NCT07181941
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Linvoseltamab, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Biospecimen Collection
Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 25, 2026, 2:34 PM EDT
Terminated Phase 2 Interventional Results available

Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts

NCT05005182
View directory record Official record
Conditions
Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Hydroxyurea, Luspatercept, Questionnaire Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 25, 2026, 2:34 PM EDT
Recruiting Phase 3 Interventional

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

NCT06022939
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bortezomib, Computed Tomography, Cyclophosphamide, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Echocardiography, Magnetic Resonance Imaging, Melphalan, Positron Emission Tomography, Stem Cell Isolation, Survey Administration
Procedure · Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
117
States / cities
Goodyear, Arizona • Tucson, Arizona • Duarte, California + 93 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 25, 2026, 2:34 PM EDT
Recruiting Phase 1 Interventional

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

NCT07133997
View directory record Official record
Conditions
Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Interventions
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Echocardiography Test, Lumbar Puncture, Multigated Acquisition Scan, Venetoclax, Vincristine
Drug · Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 2:34 PM EDT
Completed Not applicable Interventional

Salivary Gland Autotransplantation for Treatment of XRT Induced Xerostomia

NCT04007081
View directory record Official record
Conditions
Xerostomia, Head and Neck Cancer
Interventions
Bone Marrow Aspiration, Ultrasound Imaging of Salivary Glands, Salivary Assay, Quality of Life Instruments
Procedure · Diagnostic Test · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 25, 2026, 2:34 PM EDT
Recruiting Phase 2 Interventional

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

NCT06207799
View directory record Official record
Conditions
Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging
Interventions
Elranatamab, Lenalidomide, Plerixafor, Melphalan, Busulfan, G-CSF, Stem cell transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 25, 2026, 2:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant

NCT03330795
View directory record Official record
Conditions
Primary Immunodeficiency, PID
Interventions
CD3/CD19 neg allogeneic BMT
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years to 45 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 25, 2026, 2:34 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

NCT04959175
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
Mycophenolate Mofetil, Allogeneic HSCT, Fludarabine, Sirolimus, Filgrastim, Cyclophosphamide, Mesna, Total Body Irradiation (TBI)
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 85 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 2:34 PM EDT
Recruiting Phase 2 Interventional

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

NCT06661915
View directory record Official record
Conditions
Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm, Essential Thrombocythemia, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Not Otherwise Specified, Polycythemia Vera, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Iadademstat
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
31
States / cities
Irvine, California • Orange, California • Palo Alto, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 25, 2026, 2:34 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

NCT04802161
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Liposome-encapsulated Daunorubicin-Cytarabine, Pomalidomide
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
11
States / cities
Atlanta, Georgia • Kansas City, Kansas • Westwood, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 25, 2026, 2:34 PM EDT
Completed Phase 3 Interventional

Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer

NCT00002942
View directory record Official record
Conditions
Breast Cancer
Interventions
autologous bone marrow transplantation, peripheral blood stem cell transplantation
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 60 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 25, 2026, 2:34 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

NCT02879695
View directory record Official record
Conditions
Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Mixed Phenotype Acute Leukemia
Interventions
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy, Ipilimumab, Nivolumab
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
7
States / cities
New Haven, Connecticut • Lexington, Kentucky • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 25, 2026, 2:34 PM EDT
Recruiting No phase listed Observational

Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy

NCT06279572
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspirate, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 25, 2026, 2:34 PM EDT
Completed No phase listed Observational

Outcomes Data of Bone Marrow Stem Cells to Treat Hip and Knee Osteoarthritis

NCT01601951
View directory record Official record
Conditions
Hip and Knee Osteoarthritis
Interventions
Procedural, Bone Marrow concentrate injection
Other
Lead sponsor
Regenerative Pain Center, Illinois
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Des Plaines, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 25, 2026, 2:34 PM EDT